Oral Cancer in East Africa: The Need for Early Detection

By Crystal Lubbe

April 3, 2025

oral cancer East Africa

Did you know that oral cancer is a topical public health issue in East Africa? This article provides a comprehensive analysis of oral cancer in East Africa, covering epidemiology, awareness, risk factors, and clinical outcomes. The findings emphasise a growing public health concern, with tobacco use emerging as the predominant risk factor—particularly in Sudan, where the consumption of smokeless tobacco products such as toombak is widespread.

Key Insights

  • Tobacco Use: Strongly linked to oral cancer risks, particularly in Sudan. It alters the oral microbiome, aiding cancer development.
  • Late Detection: Majority of cases are diagnosed late, worsening treatment outcomes and mortality.
  • Risk Factors: Alcohol use, poor oral hygiene, age, HIV status, and human papillomavirus (HPV) infection also play significant roles in determining risk profiles.
  • Awareness and Literacy: Dentists and dental patients show higher awareness than the general public.

Background Context

Globally, oral cancer represents a major public health concern. In East Africa, the rising incidence of oral cancer is fueled by a complex interplay of lifestyle factors, infectious agents, and socioeconomic barriers. The International Agency for Research on Cancer (IARC) has recorded high oral cancer rates in the region, and recent studies have begun to elucidate the unique epidemiological and clinical profiles of oral and maxillofacial tumors in East Africa.

In Kenya, the overall prevalence of oral cancer has been reported at an all-time high of 3.6%. Oral squamous cell carcinoma (OSCC) prevalence in Sudan has been reported to range from 45.1% to 73%, while Kenyan patients present a prevalence of approximately 59.5%.

Implications

The emerging data calls for urgent and tailored public health interventions to address the distinct epidemiological patterns of oral cancer

  • Healthcare Resource Allocation: Focus on early detection and reducing Tobacco use to guide resource distribution.
  • Economic Impact: Better screening may lower late-stage treatment costs.
  • Health Outcomes: Curbing risks and improving detection can boost survival rates.

In conclusion data from Kenya and Sudan reveals a concerning oral cancer situation in East Africa. Moreover, tobacco and alcohol, advanced age, and co-infections like HIV and HPV pose major risks. Therefore, public health authorities must adopt targeted strategies quickly. Moreover, early detection, lifestyle changes—notably curbing toombak use—and better resource allocation can reduce the burden. Finally, integrating epidemiological data into policy will yield better cancer prevention and care. For more details, refer to the original research articles.

Reference url

Recent Posts

KEYTRUDA combination therapy
KEYTRUDA Combination Therapy Gains FDA Approval for Advanced Triple-Negative Breast Cancer

By João L. Carapinha

June 26, 2026

The FDA has approved KEYTRUDA combination therapy with Trodelvy as first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1 at a Combined Positive Score of 10 or greater. This marks the first regulatory nod for a PD-...
Trodelvy ADC approval
Advancements in Breast Cancer Treatment Following Trodelvy ADC Approval

By João L. Carapinha

June 25, 2026

The Trodelvy ADC approval by the European Commission delivers the first antibody-drug conjugate approved for first-line use in adults with unresectable or metastatic triple-negative breast cancer who are ineligible for PD-1 or PD-L1 inhibitors. This
Cemiplimab Cervical Cancer Access
Cemiplimab Cervical Cancer Access Navigating Treatment and Value

By João L. Carapinha

June 24, 2026

Cemiplimab Cervical Cancer Access has been endorsed by NICE for adults with recurrent or metastatic cervical cancer that has progressed after platinum-based chemotherapy, provided patients have not previously received immunotherapy. The final draft guidance confirms that this PD-1 inhibitor deliv...